CORTINOVIS DIEGO LUIGI

Crippa, V., Cordani, N., Villa, A., Malighetti, F., Villa, M., Sala, L., et al. (2025). Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0) [Altro] [10.1038/s41698-025-01114-1]. Dettaglio

Lee, S., Schulz, C., Baird, A., Prabhash, K., Kowalski, D., Szczesna, A., et al. (2025). A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study). FUTURE ONCOLOGY, 21(14), 1725-1734 [10.1080/14796694.2025.2500915]. Dettaglio

Filippi, A., García Campelo, M., Paoli, J., Kowalski, D., Bennati, C., Borghetti, P., et al. (2025). Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study. ESMO OPEN, 10(9) [10.1016/j.esmoop.2025.105560]. Dettaglio

Gelsomino, F., Boni, L., Tiseo, M., Ricciardi, S., Rocco, D., Cortinovis, D., et al. (2025). An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04–2016. LUNG CANCER, 199(January 2025) [10.1016/j.lungcan.2024.108059]. Dettaglio

Reale, M., Scattolin, D., Vitale, A., Passiglia, F., Grisanti, S., Macerelli, M., et al. (2025). Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database. LUNG CANCER, 209(November 2025) [10.1016/j.lungcan.2025.108762]. Dettaglio